Posted by Michael Wonder on 17 Feb 2023
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
16 February 2023 - EMA marketing authorisation application for leniolisib changed to standard review timetable.
Pharming announces that the EMA's CHMP has decided to shift its assessment of the marketing authorisation application for leniolisib to a standard review timetable.
